Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
Tyrosine kinase inhibitor therapy is an established standard of care for patients with NSCLC with EGFR mutations, but a worse prognosis has been observed in patients with specific EGFR exon-20 insertion mutations. Mobocertinib (TAK-788) is a novel tyrosine kinase inhibitor developed to target EGFR e...
Enregistré dans:
Auteurs principaux: | , , , , , , , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Elsevier
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/61551415e3464b25acbfc6de48caa7de |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|